 Brian Montague
Concepts (187)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prisoners | 10 | 2020 | 141 | 2.300 |
Why?
| | Prisons | 8 | 2020 | 79 | 1.680 |
Why?
| | Emergency Responders | 2 | 2022 | 35 | 1.510 |
Why?
| | HIV Infections | 20 | 2020 | 2730 | 1.450 |
Why?
| | Immunoglobulin A | 2 | 2022 | 202 | 0.860 |
Why?
| | Asymptomatic Infections | 1 | 2022 | 26 | 0.760 |
Why?
| | Viral Load | 3 | 2018 | 449 | 0.740 |
Why?
| | Antibodies, Viral | 2 | 2022 | 602 | 0.720 |
Why?
| | Patient Acceptance of Health Care | 3 | 2018 | 761 | 0.670 |
Why?
| | Continuity of Patient Care | 3 | 2018 | 273 | 0.650 |
Why?
| | Rhode Island | 10 | 2018 | 26 | 0.640 |
Why?
| | Communicable Disease Control | 2 | 2014 | 75 | 0.520 |
Why?
| | Anti-Retroviral Agents | 2 | 2016 | 231 | 0.510 |
Why?
| | Hepatitis C | 2 | 2015 | 243 | 0.490 |
Why?
| | Patient Identification Systems | 1 | 2015 | 16 | 0.490 |
Why?
| | Antiviral Agents | 3 | 2021 | 715 | 0.470 |
Why?
| | Medical Record Linkage | 1 | 2015 | 61 | 0.460 |
Why?
| | Telemedicine | 2 | 2020 | 792 | 0.440 |
Why?
| | Public-Private Sector Partnerships | 1 | 2014 | 42 | 0.430 |
Why?
| | Vulnerable Populations | 2 | 2018 | 156 | 0.370 |
Why?
| | Hepatitis B Vaccines | 1 | 2012 | 47 | 0.370 |
Why?
| | Public Health Administration | 1 | 2012 | 75 | 0.360 |
Why?
| | Hepatitis B | 1 | 2012 | 66 | 0.360 |
Why?
| | Tuberculosis | 1 | 2014 | 273 | 0.340 |
Why?
| | Health Resources | 1 | 2011 | 114 | 0.340 |
Why?
| | Vaccination | 2 | 2022 | 1347 | 0.320 |
Why?
| | Mass Screening | 6 | 2020 | 1190 | 0.290 |
Why?
| | Immunoglobulin G | 2 | 2022 | 851 | 0.290 |
Why?
| | Hyperkalemia | 1 | 2008 | 24 | 0.280 |
Why?
| | Drug Industry | 1 | 2008 | 106 | 0.260 |
Why?
| | Humans | 38 | 2024 | 129627 | 0.260 |
Why?
| | Interprofessional Relations | 1 | 2008 | 277 | 0.240 |
Why?
| | Community Health Services | 3 | 2016 | 228 | 0.240 |
Why?
| | Health Promotion | 1 | 2011 | 720 | 0.240 |
Why?
| | Health Services Accessibility | 4 | 2020 | 903 | 0.230 |
Why?
| | Electrocardiography | 1 | 2008 | 611 | 0.230 |
Why?
| | AIDS Serodiagnosis | 2 | 2014 | 23 | 0.220 |
Why?
| | Medical Informatics | 1 | 2024 | 99 | 0.210 |
Why?
| | Medical Tourism | 1 | 2023 | 9 | 0.210 |
Why?
| | Meningitis | 1 | 2023 | 79 | 0.190 |
Why?
| | Masks | 1 | 2022 | 60 | 0.190 |
Why?
| | North Carolina | 3 | 2018 | 98 | 0.190 |
Why?
| | Antiretroviral Therapy, Highly Active | 2 | 2015 | 267 | 0.190 |
Why?
| | Mycobacterium abscessus | 1 | 2023 | 107 | 0.190 |
Why?
| | Fellowships and Scholarships | 1 | 2024 | 276 | 0.180 |
Why?
| | Adult | 14 | 2021 | 35600 | 0.180 |
Why?
| | Leadership | 1 | 2024 | 357 | 0.170 |
Why?
| | Retrospective Studies | 7 | 2022 | 14522 | 0.160 |
Why?
| | Teicoplanin | 1 | 2019 | 15 | 0.160 |
Why?
| | Anti-HIV Agents | 4 | 2014 | 757 | 0.160 |
Why?
| | Carbapenem-Resistant Enterobacteriaceae | 1 | 2019 | 2 | 0.160 |
Why?
| | Quality Improvement | 3 | 2024 | 1101 | 0.160 |
Why?
| | Klebsiella Infections | 1 | 2019 | 25 | 0.150 |
Why?
| | Antibodies, Neutralizing | 1 | 2021 | 267 | 0.150 |
Why?
| | Darunavir | 1 | 2019 | 18 | 0.150 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2019 | 31 | 0.150 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2019 | 64 | 0.150 |
Why?
| | Klebsiella pneumoniae | 1 | 2019 | 42 | 0.150 |
Why?
| | beta-Lactamases | 1 | 2019 | 41 | 0.150 |
Why?
| | Drug Users | 2 | 2020 | 41 | 0.150 |
Why?
| | HIV Protease Inhibitors | 1 | 2019 | 68 | 0.150 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2023 | 353 | 0.150 |
Why?
| | Internship and Residency | 1 | 2008 | 1050 | 0.150 |
Why?
| | Patient Dropouts | 1 | 2018 | 64 | 0.150 |
Why?
| | Male | 17 | 2021 | 63671 | 0.150 |
Why?
| | HIV Integrase Inhibitors | 1 | 2019 | 69 | 0.140 |
Why?
| | Female | 17 | 2021 | 68735 | 0.140 |
Why?
| | Socioeconomic Factors | 3 | 2018 | 1213 | 0.140 |
Why?
| | Bacteremia | 1 | 2019 | 194 | 0.130 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 757 | 0.130 |
Why?
| | Aged | 8 | 2021 | 22061 | 0.130 |
Why?
| | Middle Aged | 10 | 2021 | 31136 | 0.120 |
Why?
| | Organ Transplantation | 1 | 2019 | 228 | 0.120 |
Why?
| | Budgets | 1 | 2015 | 12 | 0.120 |
Why?
| | Biostatistics | 1 | 2015 | 16 | 0.120 |
Why?
| | Marijuana Use | 1 | 2019 | 192 | 0.120 |
Why?
| | Substance Abuse, Intravenous | 2 | 2014 | 108 | 0.120 |
Why?
| | State Government | 1 | 2015 | 43 | 0.120 |
Why?
| | Referral and Consultation | 3 | 2016 | 730 | 0.120 |
Why?
| | Confidentiality | 1 | 2015 | 67 | 0.120 |
Why?
| | United States | 6 | 2020 | 13871 | 0.120 |
Why?
| | Population Surveillance | 1 | 2018 | 439 | 0.110 |
Why?
| | Drug Costs | 1 | 2015 | 100 | 0.110 |
Why?
| | Pilot Projects | 1 | 2019 | 1592 | 0.110 |
Why?
| | Tuberculosis, Meningeal | 1 | 2014 | 6 | 0.110 |
Why?
| | Healthcare Financing | 1 | 2014 | 6 | 0.110 |
Why?
| | Incidence | 3 | 2021 | 2641 | 0.110 |
Why?
| | Tuberculin Test | 1 | 2014 | 36 | 0.110 |
Why?
| | Interferon-gamma Release Tests | 1 | 2014 | 32 | 0.110 |
Why?
| | Time-to-Treatment | 1 | 2015 | 179 | 0.110 |
Why?
| | Drugs, Generic | 1 | 2013 | 21 | 0.110 |
Why?
| | Prevalence | 2 | 2020 | 2564 | 0.100 |
Why?
| | Bayes Theorem | 1 | 2015 | 375 | 0.100 |
Why?
| | Young Adult | 7 | 2021 | 12455 | 0.100 |
Why?
| | Adolescent | 7 | 2021 | 20412 | 0.100 |
Why?
| | Aged, 80 and over | 5 | 2021 | 7052 | 0.100 |
Why?
| | Opioid-Related Disorders | 1 | 2020 | 483 | 0.100 |
Why?
| | Epidemics | 1 | 2014 | 82 | 0.100 |
Why?
| | Colorado | 2 | 2019 | 4404 | 0.100 |
Why?
| | Delivery of Health Care | 1 | 2019 | 898 | 0.100 |
Why?
| | Antitubercular Agents | 1 | 2014 | 200 | 0.100 |
Why?
| | Sexually Transmitted Diseases | 1 | 2014 | 150 | 0.090 |
Why?
| | Sex Work | 1 | 2011 | 21 | 0.090 |
Why?
| | Emigrants and Immigrants | 1 | 2014 | 122 | 0.090 |
Why?
| | Refugees | 1 | 2012 | 68 | 0.090 |
Why?
| | Models, Statistical | 1 | 2015 | 625 | 0.090 |
Why?
| | Prospective Studies | 2 | 2022 | 7135 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 1501 | 0.090 |
Why?
| | Computer Simulation | 1 | 2015 | 939 | 0.090 |
Why?
| | Drug Utilization | 1 | 2011 | 171 | 0.090 |
Why?
| | Criminal Law | 1 | 2010 | 30 | 0.090 |
Why?
| | Homosexuality, Male | 1 | 2011 | 176 | 0.080 |
Why?
| | Sexual Behavior | 1 | 2014 | 481 | 0.080 |
Why?
| | Curriculum | 2 | 2024 | 920 | 0.080 |
Why?
| | Insurance, Health | 1 | 2012 | 267 | 0.080 |
Why?
| | Time Factors | 2 | 2020 | 6555 | 0.080 |
Why?
| | Regression Analysis | 1 | 2012 | 997 | 0.080 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1705 | 0.080 |
Why?
| | Sensitivity and Specificity | 1 | 2014 | 1843 | 0.080 |
Why?
| | Texas | 2 | 2020 | 237 | 0.080 |
Why?
| | Patient Compliance | 1 | 2012 | 565 | 0.070 |
Why?
| | Minority Groups | 1 | 2009 | 249 | 0.070 |
Why?
| | Program Evaluation | 1 | 2011 | 875 | 0.070 |
Why?
| | Risk Factors | 3 | 2020 | 9786 | 0.070 |
Why?
| | Brain | 1 | 2019 | 2673 | 0.070 |
Why?
| | Family | 1 | 2010 | 646 | 0.060 |
Why?
| | Emergency Service, Hospital | 1 | 2014 | 1914 | 0.050 |
Why?
| | Personal Protective Equipment | 1 | 2022 | 49 | 0.050 |
Why?
| | Observational Studies as Topic | 1 | 2022 | 110 | 0.050 |
Why?
| | Forecasting | 2 | 2014 | 361 | 0.050 |
Why?
| | Assisted Living Facilities | 1 | 2021 | 13 | 0.050 |
Why?
| | Immunization, Passive | 1 | 2021 | 86 | 0.050 |
Why?
| | Particulate Matter | 1 | 2023 | 247 | 0.040 |
Why?
| | Drug Approval | 1 | 2021 | 87 | 0.040 |
Why?
| | Infusions, Intravenous | 1 | 2021 | 399 | 0.040 |
Why?
| | Skilled Nursing Facilities | 1 | 2021 | 130 | 0.040 |
Why?
| | Off-Label Use | 1 | 2019 | 51 | 0.040 |
Why?
| | Stem Cells | 1 | 2023 | 575 | 0.040 |
Why?
| | Oxazines | 1 | 2019 | 27 | 0.040 |
Why?
| | India | 1 | 2019 | 171 | 0.040 |
Why?
| | Cohort Studies | 2 | 2019 | 5426 | 0.040 |
Why?
| | Risk-Taking | 1 | 2020 | 348 | 0.030 |
Why?
| | Pyridones | 1 | 2019 | 158 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2021 | 1875 | 0.030 |
Why?
| | Piperazines | 1 | 2019 | 340 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2019 | 1042 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1269 | 0.030 |
Why?
| | Health Personnel | 1 | 2021 | 653 | 0.030 |
Why?
| | Hospitals | 1 | 2019 | 637 | 0.030 |
Why?
| | Chronic Disease | 1 | 2020 | 1720 | 0.030 |
Why?
| | Liberia | 1 | 2014 | 7 | 0.030 |
Why?
| | Length of Stay | 1 | 2019 | 1122 | 0.030 |
Why?
| | Endemic Diseases | 1 | 2014 | 31 | 0.030 |
Why?
| | Interinstitutional Relations | 1 | 2014 | 54 | 0.030 |
Why?
| | Hospitals, Urban | 1 | 2014 | 133 | 0.030 |
Why?
| | Hospitalization | 1 | 2023 | 2057 | 0.030 |
Why?
| | Long-Term Care | 1 | 2014 | 92 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2739 | 0.030 |
Why?
| | Cost Savings | 1 | 2013 | 78 | 0.030 |
Why?
| | Sex Distribution | 1 | 2014 | 360 | 0.030 |
Why?
| | Interdisciplinary Communication | 1 | 2014 | 184 | 0.030 |
Why?
| | Africa South of the Sahara | 1 | 2012 | 42 | 0.020 |
Why?
| | Analgesics, Opioid | 1 | 2020 | 913 | 0.020 |
Why?
| | Insurance Coverage | 1 | 2014 | 219 | 0.020 |
Why?
| | Appointments and Schedules | 1 | 2012 | 85 | 0.020 |
Why?
| | Health Services Needs and Demand | 1 | 2014 | 263 | 0.020 |
Why?
| | Child, Preschool | 2 | 2019 | 10490 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2019 | 10219 | 0.020 |
Why?
| | Cost of Illness | 1 | 2014 | 277 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2019 | 3378 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2014 | 433 | 0.020 |
Why?
| | Ambulatory Care | 1 | 2014 | 506 | 0.020 |
Why?
| | Logistic Models | 1 | 2014 | 1986 | 0.020 |
Why?
| | Unsafe Sex | 1 | 2009 | 59 | 0.020 |
Why?
| | Qualitative Research | 1 | 2015 | 1219 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2019 | 5756 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 5415 | 0.020 |
Why?
| | Social Support | 1 | 2010 | 584 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 712 | 0.020 |
Why?
| | Child | 2 | 2019 | 20884 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2012 | 2720 | 0.010 |
Why?
| | Infant | 1 | 2019 | 8995 | 0.010 |
Why?
| | Risk Assessment | 1 | 2014 | 3262 | 0.010 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2012 | 1280 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2512 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3394 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2009 | 5075 | 0.010 |
Why?
|
|
Montague's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|